The European Commission has invited stakeholders to provide feedback on commitments offered by Sanofi to resolve concerns regarding potentially anti-competitive behaviour. According to the European Commission, the issue relates to a promotional campaign that may have disparaged a rival influenza vaccine. The competitor product is reportedly the only other flu vaccine recommended for patients considered vulnerable due to specific risk factors.
The Commission is now seeking input on these proposed measures to determine if they effectively address the identified competition concerns. These commitments follow an investigation into whether the communication campaign hindered fair competition within the vaccine market. Stakeholders have been invited to submit their views on the adequacy of the steps offered by the pharmaceutical company.
Source: European Commission. Read the original report ↗